The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NYMX.F | -50% | -97.18% | -51.01% | -99% |
| S&P | +15.66% | +86.6% | +13.29% | +626% |
Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.
Market-lagging returns could be written in this two-star.
These stocks just took off, but are they about to make a return trip to Earth?
| Q4 2024 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 100.0% |
| Market Cap | $9.35M | -82.6% |
| Net Income | -$857.00K | 83.9% |
| EBITDA | -$788.00K | 83.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2024 | YOY Change | |
|---|---|---|
| Net Cash | $74.00K | 5.7% |
| Inventory | 0 | 0.0% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $3.29M | 338.1% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Return On Assets | -785.44% | 0.0% |
| Return On Invested Capital | -831.50% | 82.7% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$671.36K | 20.7% |
| Operating Free Cash Flow | -$671.36K | 20.7% |
| Metric | Q4 2023 | Q3 2024 | Q4 2024 | YoY Change |
|---|---|---|---|---|
| Price to Book | -28.94 | -3.54 | -2.95 | - |
| Price to Tangible Book Value | -28.93 | -3.54 | -2.95 | - |
| Enterprise Value to EBITDA | -2.84 | -16.03 | - | |
| Total Debt | $750.00K | $2.61M | $3.29M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
